Second-look operation improves survival in suboptimal, debulked, stage III ovarian cancer [1]

International Journal of Gynecological Cancer

Volumn 15, Issue 6, 2005, Pages 1258-

  Escobar, P F ^a   Michener, C M ^a   Rose, P G ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; HUMAN; LETTER; OVARY CANCER; PRIORITY JOURNAL; SECOND LOOK SURGERY; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; OVARIAN NEOPLASMS; REOPERATION; SURVIVAL;

EID: 30944469586     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2005.00272.x     Document Type: Letter

References (6)

1. Rahaman J, Dottino P, Jennings TS, Holland J, Cohen CJ. The second-look operation improves survival in suboptimally debulked stage III ovarian cancer patients, Int J Gynecol Cancer 2005;15:19-25.
2. Griffiths CT, Grogan RH, Hall TC. Advanced ovarian cancer: primary treatment with surgery, radiotherapy, and chemotherapy. Cancer 1972;29:1-7.
3. Griffiths CT, Parker LM, Fuller AF Jr. Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 1979;63:235-40.
4. Tobias JS, Griffiths CT. Management of ovarian carcinoma: current concepts and future prospects. N Eng J Med 1976;294:818-22,877-82.
5. Williams L, Brunetto VL, Yordan E, DiSaia PJ, Creasman WT. Secondary cytoreductive surgery at second-look laparotomy in advanced ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 1997; 66:171-8.
6. Rose PG, Nerenstone S, Brady MF et al. Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004;351:2489-97.